What Haplogen Gmbh does

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, founded in 2017. According to its firmographic profile, the company is organized around an innovative genetic technology platform, a description consistent with functional genomics and gene-discovery work — an area associated with the scientific founders Thijn Brummelkamp and Sebastian Nijman, both recognized for contributions to haploid genetic screening methodology. The firm operates with a very small team of 1-10 employees, indicating a research-focused or pre-commercial operating posture rather than a scaled commercial organization.

The company has no publicly disclosed products, services, pipeline assets, customers, partnerships, pricing, or funding rounds in the available source data, and its public website (haplogen.com) returned only a verification/loading page during data collection rather than substantive content. As a result, the underlying technology architecture, target indications, go-to-market strategy, and revenue mechanics cannot be characterized from the input. The business model is therefore not discernible: the firm may be operating as an internal R&D vehicle, a technology licensor, a platform-as-a-service provider to academic or industrial partners, or a dormant entity. This represents a material information gap for any investor diligence.

From a competitive positioning standpoint, the company's principal identifiable assets are its genetic technology platform claim and the scientific pedigree of its two founders, both of whom have published extensively in functional genomics. However, no patents, granted licenses, named collaborators, or commercial deals are disclosed, so defensibility and commercialization status remain unverifiable from the source material.

Name

Haplogen Gmbh

Website

https://haplogen.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Short description

Haplogen GmbH is a privately held Vienna-based biotechnology firm founded in 2017 around an innovative genetic technology platform, operated by a 1-10 person team and led by scientific founders Thijn Brummelkamp and Sebastian Nijman. No commercial products, customers, or revenue model are disclosed.

Ownership category

akta.pro rank

Product category

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biotechnology research
• Genetic technology platform
• Drug discovery services
• Functional genomics
• Biopharmaceutical research

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Haplogen GmbH is a privately held biotechnology firm headquartered in Vienna, Austria, that operates on an innovative genetic technology platform. Founded in 2017 with 1–10 employees, the company applies genetic technologies to support biotechnology and pharmaceutical research activities.

Differentiator

Problem solved

Functional benefit

Products and services

• Genetic Technology Platform

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Emerging players

• Mission Bio: Single-cell multi-omics platform used in functional genomics and target validation workflows — adjacent enabling technology for next-generation genetic screens.
• Recursion Pharmaceuticals: AI- and high-throughput biology-driven drug discovery platform; uses large-scale functional genomics and phenotypic screens at scale — adjacent approach with a much larger platform footprint.
• Cellecta: Provider of pooled CRISPR and shRNA screening libraries and functional genomics services — comparable platform tooling used by pharma and academic labs for target discovery.

Broad incumbents

• Horizon Discovery (Revvity): Established provider of functional genomics tools, cell line engineering, and screening services — overlapping target customer base and broader portfolio spanning CRISPR and haploid-genetics-derived reagents.
• BICO Group (CELLINK): Bioconvergence platform with cell-line and tissue-engineering tools relevant to functional genomics workflows — overlapping customer base of academic and pharma R&D groups.
• Thermo Fisher Scientific: Largest life sciences tools provider, including reagents, instruments, and screening services used in functional genomics — broad incumbent serving the same end customers.

Direct peers

• Tango Therapeutics: Uses synthetic lethality and functional genomics to develop precision oncology therapeutics — overlapping methodology and target-discovery pipeline with a haploid-genetics-based platform.
• Repare Therapeutics: Synthetic lethality and genome-wide CRISPR screening platform for oncology target discovery — comparable scientific tooling and customer base (pharma partners) as Haplogen.
• KSQ Therapeutics: Functional genomics-driven drug discovery platform using CRISPR-enabled pooled screens to identify and validate novel therapeutic targets — direct overlap with Haplogen's target-discovery value proposition.
• Scenic Biotech: Also co-founded by Thijn Brummelkamp, Scenic Biotech applies haploid genetics and functional genomics to discover novel disease-modifying targets — closely mirroring Haplogen's scientific approach and platform thesis.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haplogen Gmbh